Andere Sprachen Beam Therapeutics Inc.

Aktien

A2PY7P

US07373V1052

BEAM

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 15.12.2025			% 5 Tage	Veränd. 1. Jan.
26,83 ^USD	-1,94 %		-1,00 %	+8,19 %

06.12.	Beam Therapeutics Inc. präsentiert aktualisierte Daten aus der BEACON Phase-1/2-Studie zu Ristoglogene Autogetemcel (risto-cel)	CI
04.11.	Beam Therapeutics Inc. veroffentlicht Finanzergebnisse für das dritte Quartal und die ersten neun Monate zum 30. September 2025	CI

Andere Sprachen

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions	09.12.
Beam Therapeutics Inc. Reports Updated Data from BEACON Phase 1/2 Trial of Ristoglogene Autogetemcel (risto-cel)	06.12.
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting	06.12.
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference	12.11.
Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	04.11.
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q3 Revenue $9.7M, vs. FactSet Est of $11.3M	04.11.
Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses	04.11.
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	04.11.
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	04.11.
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting	03.11.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences	25.08.
Sector Update: Health Care Stocks Decline Premarket Thursday	14.08.
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease	14.08.
Beam Therapeutics Inc. Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease	14.08.
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation	14.08.
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease	14.08.
Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls	05.08.
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	05.08.
Beam Therapeutics Q2 net loss widens more than expected	05.08.
Earnings Flash (BEAM) Beam Therapeutics Posts Q2 $1 Loss, vs. FactSet Est of $1.11 Loss	05.08.
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q2 Revenue $8.5M, vs. FactSet Est of $12.8M	05.08.
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)	05.08.
Beam Therapeutics Provides an Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency	05.08.
Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 3000 Growth Index	30.06.
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000E Value Index	30.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Bitcoin ETFs sind großartig, aber keine echte Kryptowährung: Beam CEO

Am 30. Januar 2024 um 20:17 Uhr